



CMS Update |

Current list of covered FDG PET or PET/CT indications.

	Previous Framework				New Framework	
	Diagnosis	Staging	Restaging	Treatment Monitoring	Initial Rx	Subsequent Rx
Breast	N/C	1	Cover	Cover	1	Cover
Colorectal	Cover	Cover	Cover	CED	Cover	Cover
Esophagus	Cover	Cover	Cover	CED	Cover	Cover
Head/Neck	Cover	Cover	Cover	CED	Cover	Cover
Lymphoma	Cover	Cover	Cover	CED	Cover	Cover
Melanoma	Cover	2	Cover	CED	2	Cover
NSCLC	Cover	Cover	Cover	CED	Cover	Cover
Thyroid	Cover	Cover	3	CED	Cover	3
Brain	CED	CED	CED	CED	Cover	CED
Cervix	CED	Cover/CED	Cover/CED	CED	Cover/CED	Cover
Ovary	CED	CED	CED	CED	Cover	Cover
Myeloma	CED	CED	CED	CED	Cover	Cover
Pancreas	CED	CED	CED	CED	Cover	CED
Prostate	CED	CED	CED	CED	N/C	CED
Small Cell Lung Cancer	CED	CED	CED	CED	Cover	CED
Testes	CED	CED	CED	CED	Cover	CED
All Other Solid Tumors	CED	CED	CED	CED	Cover	CED

1 - Covered for metastatic disease. Non-covered for staging of axillary lymph nodes.

2 - Melanoma: Non-covered for initial staging of regional lymph nodes.

3 - Thyroid: Covered for restaging of follicular cell types.



CMS Update |

Current list of covered FDG PET or PET/CT indications.

New Coverage for Initial Treatment Strategy:

- **Myeloma:** CMS will nationally cover the use of FDG PET imaging to determine initial treatment strategy in patients with myeloma.
- **Prostate:** CMS will nationally non-cover the use of FDG PET imaging to determine initial treatment strategy in patients with adenocarcinoma of the prostate.
- All other cancers not listed herein: CMS will nationally cover the use of FDG PET imaging to determine initial treatment strategy in patients with all other cancers not listed herein provided under CED.

Subsequent Treatment Strategy

The CMS will non-cover FDG PET imaging for subsequent anti-tumor treatment strategy for tumor types other than breast, colorectal, esophagus, head and neck (non-CNS/thyroid), lymphoma, melanoma, non-small cell lung, and thyroid, unless the FDG PET is provided under CED.

New Coverage for Subsequent Treatment Strategy:

- **Ovarian:** CMS will nationally cover the use of FDG PET imaging to determine subsequent treatment strategy in patients with ovarian cancer.
- **Cervical:** CMS will nationally cover the use of FDG PET imaging to determine subsequent treatment strategy in patients with cervical cancer.
- **Myeloma:** CMS will nationally cover the use of FDG PET imaging to determine subsequent treatment strategy in patients with myeloma.
- All other cancers not listed herein: CMS will nationally cover the use of FDG PET imaging to determine subsequent treatment strategy in patients with all other cancers not listed herein provided under CED.

For additional information, please reference the CMS Manuals:

Pub 100-03 Medicare National Coverage Determinations; Transmittal 106; FDG PET for solid tumors and myeloma: www.cms.hhs.gov/transmittals/downloads/R106NCD.pdf

Pub 100-04 Medicare Claims Processing; Transmittal 1817; FDG PET for solid tumors and myeloma: www.cms.hhs.gov/transmittals/downloads/R1817CP.pdf

IBA Molecular, North America, Inc. Disclaimer: This information is provided by IBA Molecular North America Inc. (together with its affiliates "IBA") as educational guidance only and is not intended to increase or maximize reimbursement by any payer. Diagnosis and procedure coding is dependent on documentation in the patient's medical record. Federal law prohibits fraudulent statements made on insurance claim submissions, and violations can result in both civil and criminal penalties. IBA strongly recommends that you consult your third-party payers with regard to local coverage, coding and reimbursement policies and follow all applicable federal, state and local laws when billing for reimbursement and review and confirm reimbursement policies with your own legal or other professional advisors. Please note Medicare's Correct Coding Initiative is reviewed and updated several times a year and commercial payer policies vary and should be carefully reviewed. Revised 10/15/2009